 This is an open-label, single arm roll-over study of Study WRI-GEV-007, A Phase IIIa Study of SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer Patients. Those patients who have exhibited disease progression according to iRECIST criteria will be eligible to roll over into this study, at the Investigators discretion. Following discussion with the Sponsor, the Investigator can have the patient treated with one of the following regimens: 